Home/Filings/4/0000950170-25-039021
4//SEC Filing

KENNEY CHRISTOPHER JOHN 4

Accession 0000950170-25-039021

CIK 0001582313other

Filed

Mar 12, 8:00 PM ET

Accepted

Mar 13, 7:31 PM ET

Size

7.4 KB

Accession

0000950170-25-039021

Insider Transaction Report

Form 4
Period: 2025-03-12
KENNEY CHRISTOPHER JOHN
Chief Medical Officer
Transactions
  • Award

    Share Option (Right to Buy)

    2025-03-12+80,00080,000 total
    Exercise: $35.48Exp: 2035-03-11Common Shares (80,000 underlying)
  • Award

    Restricted Share Units

    2025-03-12+15,00015,000 total
    Exercise: $0.00Common Shares (15,000 underlying)
Footnotes (2)
  • [F1]Vesting 25% on March 12, 2026, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
  • [F2]Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026.

Documents

1 file

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

Entity typeother

Related Parties

1
  • filerCIK 0001880129

Filing Metadata

Form type
4
Filed
Mar 12, 8:00 PM ET
Accepted
Mar 13, 7:31 PM ET
Size
7.4 KB